Basic/Clinical Science Session
SGLT2 Inhibition for CKD: Results of the DAPA-CKD Trial
October 23, 2020 | 02:30 PM - 03:30 PM
Location: Live-Streamed
Session Description
The DAPA-CKD trial assessed the SGLT2 inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). The trial was stopped early for overwhelming efficacy. This session presents the results of the DAPA-CKD trial with a focus on patients without T2D.
Learning Objective(s)
- Discuss mechanisms of action of SGLT2 inhibitors in patients with and without T2D
- Describe the DAPA-CKD trial design and highlight differences from other trials
- Discuss the DAPA-CKD trial results with a focus on patients without T2D
Learning Pathway(s)
- Chronic Kidney Disease
- Diabetes and Metabolism
Moderator
- Meg J. Jardine, MBBS, PhD
Presentations
- Rationale and Design of the DAPA-CKD Trial
02:30 PM - 02:50 PM
Hiddo Jan L Heerspink, PhD
- Results of the DAPA-CKD Trial
02:50 PM - 03:10 PM
David C. Wheeler, MD
- Clinical Perspective on the DAPA-CKD Trial
03:10 PM - 03:30 PM
Robert D. Toto, MD